Leveraging crowdsourcing via opnMe.com for ‘More Green Medicines’ and a healthier planet
Solvents account for a major part of the total chemical waste that is generated during the synthesis of active pharmaceutical ingredients. A reduction in their use is highly desirable from an economic and environmental viewpoint.
Dipolar aprotic solvents are particularly challenging - they have a unique reactivity and utility in several chemical transformations, but they also possess serious undesirable health and safety characteristics.
Mechanochemistry, which works typically under solvent-free conditions, holds, therefore, promise for increasing the sustainability of chemical processes, including those using dipolar aprotic solvents.
Via our Open Innovation Portal opnMe, we are now inviting scientific experts to propose new screening platforms for high-throughput experimentation in microtiter plates under controlled mechanochemical conditions that would allow, in a second phase, a seamless transfer to scale-up mechanochemical platforms for production purposes.
Would you like to contribute?
If you have an innovative idea on how to address this challenge and are interested in collaborating with our team of experts at the Chemical Development Department in Germany, submit your proposal until April 18, 2023.
The selected project will receive an $80,000 grant for the implementation of an idea that can be completed within 12 months and has the potential for tangible impact. We look forward to your submission and working side-by-side with you!
Learn more and apply through our Open Innovation Portal, opnMe.com
About Boehringer Ingelheim
As a leading research-driven biopharmaceutical company, Boehringer Ingelheim is working on breakthrough therapies that transform lives, today and for generations to come. Boehringer Ingelheim’s commitment towards a healthier and more sustainable future is firmly anchored in our corporate philosophy since its founding and translated through our Sustainable Development for Generations framework. To minimize the environmental footprint of our future life-changing medicines, we are focusing on sustainable science and innovation, based on the principles of eco-design and green chemistry, starting from the synthesis of the biological or small molecule drug substance all the way to the packaged product and device.
The opnMe initiative originated from Boehringer Ingelheim’s Discovery Research with the aim to interact with researchers for the advancement of early preclinical projects in healthcare. opnMe has over 4,500 registered users and received 1,600 collaboration proposals since its inception in 2017. We have successfully interacted with scientists from 70 countries, who either accessed our well-characterized molecules for preclinical research or collaborated with us on research projects with an impact for patients in need.
Our position towards Intellectual Property (IP)
All results and all IP therein generated by the researcher (institute) in the performance of the project will be jointly owned. Generally, each party may freely use the results, without further obligations to the other party. At the same time, however, the parties agree that in order to contribute to the advancement of science for the benefit of the public and to allow the scientific community and industry to use any results following joint publication, they will abstain from pursuing exclusive intellectual property protection with respect to any results. Particularly, neither party shall file for a patent right pertaining to any results anywhere in the world and in any field.